medigraphic.com

2009, Number 4

<< Back Next >>

Rev Educ Bioquimica 2009; 28 (4)

Control molecular de la inflamación: Regulación de los receptores tipo Toll

Domínguez NA, Zentella DA, Velázquez RJR

Language: Spanish
References: 15
Page: 125-131
PDF size: 343.48 Kb.


ABSTRACT

The origin and intensity of most inflammatory illnesses is caused by the unbalanced production of mediators that regulate these processes. In an attempt to better understand these pathologies, a Toll like receptors family that detect molecular patterns associated to danger (DAMP's) has been identified; recognition of these signals by these family of receptors starts intracellular processes that lead to the expression of inflammatory mediators. The current question is to understand how these mechanisms are controlled and what are the dysfunctions that lead to disease states; this review cover how are activated and regulated the signaling pathways of these receptors family.


REFERENCES

  1. Kawai T, Akira S (2007) TLRsignaling. Semin Immunol 19(1):24-32.

  2. Bianchi M E (2007) DAMPs, PAMPs and alarmins: All we need to know about danger. J Leukoc Biol 81(1): 1-5.

  3. O'Neill LAJ (2004) TLRs: ProfessorMechnikov, sit on your hat. Trends Immunol 25(12): 687-693.

  4. KarinM(1998) The NF- B activation pathway: Its regulation and role in inflammation and cell survival. Cancer J Sci Am 4(SUPPL. 1).

  5. O'Neill L A J (2008) The interleukin-1 receptor/Tolllike receptor superfamily: 10 years of progress. Immunol Rev 226:10-18.

  6. Takeda K, Akira S (2005) Toll-like receptors in innate immunity. Int Immunol 17(1):1-14.

  7. Krieg A M (2007) TLR9 and DNA 'feel' RAGE. Nat Immunol 8(5):475-477.

  8. Akashi-Takamura S, Miyake K (2008) TLR accessory molecules. Curr Opin Immunol 20(4):420-425.

  9. Li X X, Qin J Z (2005) Modulation of Toll-interleukin 1 receptor mediated signaling. J Mol Med 83(4):258- 266.

  10. Foster S L, Medzhitov R (2009) Gene-specific control of the TLR-induced inflammatory response. Clin Immunol 130(1):7-15.

  11. Horng T, BartonGM, Flavell RA,Medzhitov R. (2002) The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 420 (6913): 329-333.

  12. Jefferies C A, Doyle S, Brunner C, Dunne A, Brint E, Wietek C,Walch E,Wirth T, O'Neill LAJ (2003) Bruton's tyrosine kinase is a toll/interleukin- 1 receptor domainbinding protein that participates in nuclear factor kappa B activation by toll-like receptor 4. J Biol Chem278(28): 26258-26264.

  13. Liew F Y, Xu D M, Brint E K and O'Neill LA J (2005) Negative regulation of Toll-like receptor-mediated immune responses. Nat Rev Immunol 5(6):446-458.

  14. Janssens S, Burns K, Vercammen E, Tschopp J, Beyaert R (2003) MyD88(S), a splice variant of MyD88, differentially modulates NF-kappa B- and AP-1- dependent gene expression. FEBS Lett 548(1-3):103- 107.

  15. Kobayashi K S, Flavell RA(2004) Shielding the doubleedged sword Negative regulation of the innate immune system. J Leukoc Biol 75(3):428-433.




2020     |     www.medigraphic.com